Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends - Regeneron Pharmaceuticals (NASDA

Benzinga's options scanner has just identified more than 16 option transactions on Regeneron Pharmaceuticals (NASDAQ:REGN), with a cumulative value of $427,360. Concurrently, our algorithms picked up 14 puts, worth a total of 418,490.

Projected Price Targets

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $880.0 and $905.0 for Regeneron Pharmaceuticals, spanning the last three months.

Volume & Open Interest Development

In terms of liquidity and interest, the mean open interest for Regeneron Pharmaceuticals options trades today is 231.5 with a total volume of 1,641.00.

In the following chart, we are able to follow the development of volume and open interest of call and put options for Regeneron Pharmaceuticals's big money trades within a strike price range of $880.0 to $905.0 over the last 30 days.

Regeneron Pharmaceuticals Call and Put Volume: 30-Day Overview

Largest Options Trades Observed:

Symbol	PUT/CALL	Trade Type	Sentiment	Exp. Date	Ask	Bid	Price	Strike Price	Total Trade Price	Open Interest	Volume
REGN	CALL	TRADE	BULLISH	01/17/25	$99.3	$91.0	$97.35	$900.00	$77.8K	576	2
REGN	PUT	TRADE	BEARISH	05/17/24	$16.8	$14.3	$16.5	$880.00	$37.9K	35	53
REGN	PUT	TRADE	BEARISH	05/17/24	$16.5	$14.1	$16.5	$880.00	$36.3K	35	39
REGN	PUT	TRADE	BULLISH	05/03/24	$22.2	$19.6	$19.6	$900.00	$33.3K	315	138
REGN	PUT	TRADE	BULLISH	05/03/24	$23.8	$20.4	$20.4	$900.00	$32.6K	315	59

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

Present Market Standing of Regeneron Pharmaceuticals

With a volume of 66,439, the price of REGN is up 0.24% at $894.58.
RSI indicators hint that the underlying stock may be approaching oversold.
Next earnings are expected to be released in 2 days.

Professional Analyst Ratings for Regeneron Pharmaceuticals

A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $1033.6.

An analyst from TD Cowen persists with their Buy rating on Regeneron Pharmaceuticals, maintaining a target price of $1030.
An analyst from Cantor Fitzgerald downgraded its action to Neutral with a price target of $925.
Maintaining their stance, an analyst from UBS continues to hold a Buy rating for Regeneron Pharmaceuticals, targeting a price of $1099.
In a cautious move, an analyst from RBC Capital downgraded its rating to Outperform, setting a price target of $1189.
Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Neutral with a new price target of $925.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.

If you want to stay updated on the latest options trades for Regeneron Pharmaceuticals, Benzinga Pro gives you real-time options trades alerts.

REGNRegeneron Pharmaceuticals Inc

$676.751.85%

Overview

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.